A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
A social media poll by billionaire Mark Cuban reveals a near-even split on which part of U.S. health insurance is more financially painful—premiums or deductibles. The results, and the outpouring of personal stories in the replies, underscore a system many describe as forcing impossible choices amid relentlessly rising costs.
After a punishing year of underperformance and operational setbacks, Baxter International faces a skeptical analyst community. While some see deep value, the consensus remains firmly on hold as the company navigates product challenges and revised guidance.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
Shares of The Pennant Group (PNTG) have climbed 15% in recent months, yet remain below yearly highs. With a P/E ratio significantly above the industry average, analysts are divided on whether the stock's growth prospects justify its premium valuation.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
A dramatic surge in SuperX AI Technology's share price has spotlighted its concentrated ownership structure, with private companies holding a dominant 34% stake and reaping the largest rewards from the recent rally. As the AI-driven healthcare sector heats up, investor attention turns to who holds the reins at this promising but closely held firm.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
Wells Fargo lowered its price target on UnitedHealth Group (UNH) following its Q4 report and a disappointing Medicare rate proposal from regulators, highlighting pressures on the healthcare giant's key growth engine.
Auna S.A. (NYSE:AUNA) saw its market value shed $55 million last week, with its largest shareholder group—private equity firms—absorbing the heaviest losses. We analyze the ownership structure and what it means for the Latin American healthcare provider's future.
A deep dive into Guardian Pharmacy Services (NYSE:GRDN) using a discounted cash flow model suggests its current share price is hovering close to its estimated intrinsic value. While the analysis provides a quantitative benchmark, investors are cautioned that valuation is just one piece of the puzzle in a complex and regulated healthcare sector.
A major grant from Centene's foundation aims to tackle housing insecurity for justice-involved individuals in Chicago, spotlighting the healthcare giant's community investments as its stock faces persistent headwinds.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
Amidst global market volatility, a focused look at Asia reveals companies with resilient fundamentals trading at compelling valuations. We analyze three such names from the education, healthcare, and chemical sectors.
As regional markets navigate post-oil volatility and geopolitical shifts, a closer look reveals three penny stocks—from Turkish media to Saudi healthcare—that combine resilient balance sheets with high-risk, high-reward potential for the discerning investor.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
In a significant move to bolster its healthcare services and retain staff, Walmart is creating thousands of new leadership positions and raising wages for pharmacy technicians across its U.S. stores.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
